SCHEMBL4975263

SCHEMBL4975263

Cn1ccnc1-c1cc2nccc(Oc3ccc(NC(=O)c4cccc(-c5ccccc5)c4F)cc3F)c2s1

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.68
MST1R Q04912 12/20 0.68
KDR P35968 8/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977779 0.88 MET (0.70) METMST1RKDR
SCHEMBL4977541 0.87 MET (0.69) METMST1RKDR
SCHEMBL4975121 0.87 MET (0.72) METMST1RKDR
SCHEMBL308075 0.83 MET (0.76) METMST1RKDR
SCHEMBL4301392 0.83 MET (0.70) METMST1RKDR
SCHEMBL14262952 0.82 MET (0.69) METMST1RKDR
SCHEMBL306762 0.82 MET (0.69) METMST1RKDR
SCHEMBL3560490 0.82 MET (0.86) METMST1RKDR
SCHEMBL4975657 0.81 MET (1.00) METMST1RKDR
SCHEMBL307647 0.80 MET (0.71) METMST1RKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 US disclosed
WO-2007107005-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE, INC. (CA) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET MET 3/4885MST1R 104/4885KDR 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.